Subtopic Deep Dive
Metastatic Uveal Melanoma Prognostic Factors
Research Guide
What is Metastatic Uveal Melanoma Prognostic Factors?
Metastatic Uveal Melanoma Prognostic Factors are molecular and clinical biomarkers, including BAP1 mutations, GNA11 mutations, and gene expression class 1/2, that predict liver metastasis risk and survival in uveal melanoma patients.
Uveal melanoma metastasizes to the liver in ~50% of cases within 10 years, with prognostic factors like chromosomal 8p loss and class 2 gene expression linked to poor outcomes (Onken et al., 2004; Harbour et al., 2010). BAP1 mutations strongly associate with metastatic progression (Harbour et al., 2010, 1455 citations). Long-term studies confirm metastasis as the primary cause of death (Kujala et al., 2003, 1031 citations). Over 10 key papers from provided list address these factors.
Why It Matters
Prognostic factors stratify patients for adjuvant trials and surveillance, as tebentafusp extends survival in metastatic cases (Nathan et al., 2021, 794 citations). BAP1 and GNA11 mutations guide risk assessment, with 83% of uveal melanomas harboring GNAQ/GNA11 alterations (Van Raamsdonk et al., 2010, 1446 citations). Gene expression profiling distinguishes class 1 (low-risk) from class 2 (high-risk) tumors, informing trial eligibility (Onken et al., 2004, 746 citations). These biomarkers enable personalized monitoring given the 50% metastasis rate.
Key Research Challenges
Heterogeneity in Mutation Profiles
BAP1 mutations predict metastasis but vary across tumors, complicating uniform prognostic models (Harbour et al., 2010). GNA11 and GNAQ mutations occur in 83% of cases yet do not always correlate with survival (Van Raamsdonk et al., 2010). Integrating these with TERT promoter mutations remains inconsistent (Vinagre et al., 2013).
Distinguishing Gene Expression Classes
Class 1/2 profiling predicts metastatic death but requires validation across cohorts (Onken et al., 2004). Long-term survival data show class 2 tumors metastasize later, challenging early predictions (Kujala et al., 2003). Assay reproducibility across labs poses barriers to clinical adoption.
Limited Systemic Treatment Response
Despite tebentafusp's OS benefit, prognostic factors fail to predict immunotherapy response (Nathan et al., 2021). Historical data highlight socioeconomic influences on noncutaneous melanoma survival (Chang et al., 1998). Biomarker-stratified trials lack sufficient endpoints for rare metastatic cohorts.
Essential Papers
The National Cancer Data Base report on cutaneous and noncutaneous melanoma
Alfred E. Chang, Lucy Hynds Karnell, Herman R. Menck · 1998 · Cancer · 1.6K citations
Treatment of early stage cutaneous melanoma resulted in excellent patient outcomes. In addition to conventional prognostic factors, socioeconomic factors were found to be associated with survival.
Frequent Mutation of <i>BAP1</i> in Metastasizing Uveal Melanomas
J. William Harbour, Michael D. Onken, Elisha Roberson et al. · 2010 · Science · 1.5K citations
An Eye on Metastasis Despite the considerable progress being made in elucidating the cell biology of metastasis, little is known about the genetic alterations that promote metastasis of human tumor...
Mutations in <i>GNA11</i> in Uveal Melanoma
Catherine D. Van Raamsdonk, Klaus Griewank, Michelle B. Crosby et al. · 2010 · New England Journal of Medicine · 1.4K citations
Of the uveal melanomas we analyzed, 83% had somatic mutations in GNAQ or GNA11. Constitutive activation of the pathway involving these two genes appears to be a major contributor to the development...
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Emma Kujala, Teemu Ma ̈kitie, Tero Kivelä · 2003 · Investigative Ophthalmology & Visual Science · 1.0K citations
Metastatic uveal melanoma was the leading single cause of death throughout the study. Cumulative incidences provide a sound basis for patient counseling and design of trials.
Frequency of TERT promoter mutations in human cancers
João Vinagre, Ana Paula de Almeida, Helena Pópulo et al. · 2013 · Nature Communications · 878 citations
Reactivation of telomerase has been implicated in human tumorigenesis, but the underlying mechanisms remain poorly understood. Here we report the presence of recurrent somatic mutations in the TERT...
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C. Hassel, Piotr Rutkowski et al. · 2021 · New England Journal of Medicine · 794 citations
Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov...
Uveal melanoma
Martine J. Jager, Carol L. Shields, Colleen M. Cebulla et al. · 2020 · Nature Reviews Disease Primers · 779 citations
Reading Guide
Foundational Papers
Start with Harbour et al. (2010, 1455 citations) for BAP1-metastasis link; Van Raamsdonk et al. (2010, 1446 citations) for GNA11 prevalence; Onken et al. (2004, 746 citations) for gene expression classes; Kujala et al. (2003, 1031 citations) for survival baselines.
Recent Advances
Nathan et al. (2021, 794 citations) on tebentafusp OS benefit; Jager et al. (2020, 779 citations) uveal melanoma primer integrating biomarkers.
Core Methods
Sequencing for BAP1/GNA11/TERT mutations (Harbour 2010; Van Raamsdonk 2010; Vinagre 2013); microarray for class 1/2 profiling (Onken 2004); cumulative incidence analysis for metastasis timing (Kujala 2003).
How PapersFlow Helps You Research Metastatic Uveal Melanoma Prognostic Factors
Discover & Search
Research Agent uses searchPapers and citationGraph to map Harbour et al. (2010) connections, revealing 1455 citations linking BAP1 to metastasis; exaSearch uncovers class 1/2 extensions from Onken et al. (2004); findSimilarPapers expands to GNA11 variants (Van Raamsdonk et al., 2010).
Analyze & Verify
Analysis Agent applies readPaperContent to extract mutation frequencies from Harbour (2010), then verifyResponse with CoVe chain-of-verification cross-checks against Kujala (2003) survival data; runPythonAnalysis computes Kaplan-Meier curves from extracted OS stats with GRADE grading for evidence strength in tebentafusp trial (Nathan et al., 2021).
Synthesize & Write
Synthesis Agent detects gaps in BAP1/GNA11 integration via contradiction flagging across papers; Writing Agent uses latexEditText for prognostic model sections, latexSyncCitations for 10+ references, and latexCompile for trial-ready reports; exportMermaid visualizes class 1/2 decision trees.
Use Cases
"Extract survival data from uveal melanoma papers and plot metastasis-free survival curves."
Research Agent → searchPapers('metastatic uveal melanoma prognosis') → Analysis Agent → readPaperContent(Kujala 2003) → runPythonAnalysis(pandas/matplotlib for Kaplan-Meier from cumulative incidences) → matplotlib plot of 10-year metastasis rates.
"Draft LaTeX review on BAP1 prognostic role with citations and figure."
Synthesis Agent → gap detection(Harbour 2010 + Onken 2004) → Writing Agent → latexEditText('BAP1 section') → latexSyncCitations(10 papers) → latexGenerateFigure(class 2 risk diagram) → latexCompile → PDF with integrated survival table.
"Find code for gene expression class 1/2 analysis in uveal melanoma papers."
Research Agent → paperExtractUrls(Onken 2004) → paperFindGithubRepo('uveal melanoma gene expression') → githubRepoInspect → runPythonAnalysis(RNA-seq pipeline sandbox) → validated class prediction script.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ uveal melanoma papers: searchPapers → citationGraph → DeepScan 7-step verification with CoVe checkpoints on BAP1 survival claims. Theorizer generates hypotheses linking TERT mutations to class 2 progression (Vinagre 2013 → synthesis). DeepScan analyzes tebentafusp OS data (Nathan 2021) with runPythonAnalysis for subgroup stats.
Frequently Asked Questions
What defines metastatic uveal melanoma prognostic factors?
Key factors include BAP1 mutations predicting metastasis (Harbour et al., 2010), GNA11 mutations in 83% of cases (Van Raamsdonk et al., 2010), and gene expression class 1/2 for metastatic risk (Onken et al., 2004).
What methods identify these prognostic factors?
Gene expression profiling clusters tumors into class 1/2 (Onken et al., 2004); sequencing detects BAP1/GNA11 mutations (Harbour et al., 2010; Van Raamsdonk et al., 2010); long-term cohort studies compute cumulative metastasis incidences (Kujala et al., 2003).
What are the most cited papers?
Top papers: Chang et al. (1998, 1630 citations) on melanoma prognosis; Harbour et al. (2010, 1455 citations) on BAP1; Van Raamsdonk et al. (2010, 1446 citations) on GNA11; Kujala et al. (2003, 1031 citations) on long-term survival.
What open problems persist?
Integrating BAP1, GNA11, TERT mutations into unified models; predicting tebentafusp response (Nathan et al., 2021); standardizing class 1/2 assays for trials despite cohort variability (Onken et al., 2004).
Research Ocular Oncology and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Metastatic Uveal Melanoma Prognostic Factors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Ocular Oncology and Treatments Research Guide